Which drugs does patent RE43797 protect, and when does it expire?
Patent RE43797 protects KUVAN and is included in two NDAs. There have been three Paragraph IV challenges on Kuvan.
Protection for KUVAN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-four patent family members in eighteen countries.